Elotuzumab for the Treatment of JAK2-Mutated Myelofibrosis

Clinical trial NCT04517851 · ACTIVE_NOT_RECRUITING

Trial details

NCT number: NCT04517851
Sponsor: M.D. Anderson Cancer Center
Status: ACTIVE_NOT_RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

Myelofibrosis Transformation in Essential Thrombocythemia Polycythemia Vera, Post-Polycythemic Myelofibrosis Phase Primary Myelofibrosis

Start date: 2021-02-10
Primary completion: 2027-12-31
Enrollment: 15

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.